OPKO Health

OPKO Health to Participate in the Jefferies Global Healthcare Conference

Retrieved on: 
星期五, 五月 31, 2024
Conference, OPKO Health, Marriott Marquis, Health

MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City.

Key Points: 
  • MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City.
  • Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Thursday, June 6th at 10:30 a.m. Eastern time.

Boston Pharmaceuticals Announces Former NIH Director, Dr. Elias Zerhouni, As the New Chair of Its Board of Directors

Retrieved on: 
星期四, 五月 23, 2024
Biotechnology, Pharmaceutical, Health, Sanofi, Bangladesh Technical Education Board, Executive Committee, MASH, Chair, Hepatology, Biomedical engineering, Biomedicine, Medication, Johns Hopkins University, OPKO Health, FGF21, Pharmaceutical industry

Dr. Zerhouni has been a Board member and Scientific Advisor at Boston Pharmaceuticals since 2021.

Key Points: 
  • Dr. Zerhouni has been a Board member and Scientific Advisor at Boston Pharmaceuticals since 2021.
  • In assuming the position of Chair, he will now work even more closely with Sophie Kornowski, CEO of Boston Pharmaceuticals, her team, and the community of liver experts as the company’s promising drug candidates accelerate their development.
  • I also want to thank Stefan for all of his many and sizeable contributions and accomplishments during his time as a colleague.
  • He is, since 2020, a member of the Board at B-Flexion and is also President and Vice Chairman of OPKO Health .

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

Retrieved on: 
星期二, 五月 7, 2024
Modex, Debt-to-GDP ratio, FDA, Sale, International, Growth hormone, Safety, PIN, Pharmacokinetics, OPKO Health, Health, Research, Growth, IND, Hart–Scott–Rodino Antitrust Improvements Act, Operating cost, Labcorp, Intellectual property, Growth hormone therapy, Therapy, Note

MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024.

Key Points: 
  • MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024.
  • First quarter business highlights include the following:
    Entered into an agreement with Labcorp to sell select assets of BioReference Health.
  • First quarter 2024 results included a non-cash, non-recurring expense of $26.3 million related to an embedded derivative as part of our convertible debt.
  • OPKO’s senior management will provide a business update, discuss first quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time.

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

Retrieved on: 
星期五, 五月 3, 2024
OPKO Health, Health, International, PIN

MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024.

Key Points: 
  • MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024.
  • OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time.
  • Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator.
  • A telephone replay will be available until May 21, 2024 by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 6926223.

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Retrieved on: 
星期三, 三月 20, 2024
Zealand Pharma, Plasma, Rat, LC-MS/MS, Short bowel syndrome, Half-life, Inflammation, Patient, Tablet, Teduglutide, POC, OPKO Health, Injection, Entera, Pharmaceutical industry

The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.

Key Points: 
  • The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.
  • Currently, the only approved GLP-2 agonist, which is marketed under the name Gattex® (teduglutide), requires daily sub-cutaneous injections.
  • Entera and OPKO completed a proof of concept (PoC) single dose pharmacokinetic study in rodents as the first validation for oral administration of the GLP-2 treatment.
  • This data is consistent with previously reported PK data relating to OPKO’s GLP-2 peptide’s long acting profile, which had initially been developed as a weekly subcutaneous injection.

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
星期五, 三月 8, 2024
OXM, Woman, Injection, Research, Bone fracture, Clinical research associate, Type D, FDA, BMD, PTH, Food, Hypoparathyroidism, Obesity, Coeliac disease, Weight loss, Oxyntomodulin, Cmax, Elective surgery, Sport, Short bowel syndrome, OPKO Health, DSM-IV codes, Ecosystem, SABRE, Patient, D&O, Intellectual property, Fracture, Athlete, Sports medicine, Tablet, Osteoporosis, Insurance

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Retrieved on: 
星期二, 三月 5, 2024
Infection, Fungal infection, CROI, NIH, AIDS, Vaccine Research Center, ACTG, Conference, Antibody, Safety, OPKO Health, Therapy, Pharmacokinetics, AIDS Clinical Trials Group, Modex, Trial of the century, HIV, HIV/AIDS, Immune system, Vaccine

WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus (HIV), at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.

Key Points: 
  • These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.
  • The study enrolled 52 participants and was conducted by the AIDS Clinical Trials Group (ACTG), a clinical trials network funded by the National Institute of Allergy and Infectious Diseases, NIH.
  • The antibody was safe and well-tolerated at all dose levels and via both intravenous and subcutaneous administration.
  • These clinical data on an HIV multispecific antibody inform the future advancement of such antibodies for the prevention and treatment of HIV and provide strong rationale for the development of current and future antibody products.

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

Retrieved on: 
星期三, 二月 28, 2024
Research, Doctor of Philosophy, General partnership, Drug development, Growth, Frustration, University, Chronic pain, SUNY, Biomedical sciences, Epilepsy, Neurology, Rett syndrome, Smith, Kline & French, Acadia Pharmaceuticals, School, University at Buffalo, Biotechnology, ATyr Pharma, Health, Neurotoxicity, Cell, Therapy, DSM-IV codes, Brain, Neuropharmacology, Proteostasis, Amathus, Record, Drug discovery, Peripheral neuropathy, MPS, Physics, OPKO Health, Genomics, Acquisition, EMD, LoDo, Denver, MD, Organoid, Multiple sclerosis, Prevalence, Brown University, Brandeis University, Serono, Patient, Disease, GSK plc, Pharmaceutical industry

Dr. Pfost noted, “AxoSim embodies the entrepreneur’s sweet spot--when market need, technological innovation, timing and team all align. The growing prevalence of neurological diseases places enormous burdens on patients, their families and society. Yet despite billions in investment, neurology R&D continues to disappoint. AxoSim’s transformational approach addresses a key contributor to these failures—the lack of relevant disease models—by providing functional human data from its microphysiological system (MPS) organoid technologies early in the process. AxoSim aims to become an industry leader in helping to deliver urgently needed new drugs and I welcome the opportunity to contribute to its success.”

Key Points: 
  • Dr. Pfost and Dr. Weiner have decades of experience in building successful biotechnology companies spanning therapeutics, diagnostics and life science tools and technologies.
  • “Our recent acquisition of a third platform technology positions AxoSim for growth, and we are fortunate to have these two talented industry veterans assuming key leadership roles,” said Lowry Curley, PhD, co-founder and Chief Executive Officer of AxoSim.
  • “Dale and Dave bring successful track records in building life sciences businesses, with broad and complementary skill sets.
  • Dale’s work in life science tools and venture finance is highly relevant, as is Dave’s expertise in leading neurological drug discovery and clinical development.

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
星期二, 二月 27, 2024
International, Pfizer, Operating cost, Growth hormone therapy, Merck, PIN, Note, Health, REACH, COVID-19 testing, Sale, Storefront, Debt-to-GDP ratio, Epstein–Barr virus, COVID-19, GeneDx, OPKO Health, Intellectual property, Modex, Immunity, Ali Baba, Research

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.

Key Points: 
  • MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
    Business highlights from the fourth quarter and subsequent weeks included the following:
    ModeX advanced its antiviral and immune-oncology product pipeline.
  • Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.
  • Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter.

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Retrieved on: 
星期四, 二月 22, 2024
International, Health, OPKO Health, PIN

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024.

Key Points: 
  • MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024.
  • OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time.
  • Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator.
  • A telephone replay will be available until March 5, 2024 by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 6034226.